UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application

Journal of antimicrobial chemotherapy, 2014-05, Vol.69 (5), p.1325-1329

2014

Link zum Volltext

Verfügbarkeit prüfen

Stabilization of atherosclerotic plaques: an update

European heart journal, 2013-11, Vol.34 (42), p.3251-3258

2013

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

The Journal of infectious diseases, 2010-03, Vol.201 (6), p.803-813

2010

Link zum Volltext

Verfügbarkeit prüfen

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel

Clinical infectious diseases, 2008-07, Vol.47 (2), p.266-285

2008

Link zum Volltext

Verfügbarkeit prüfen

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

Clinical infectious diseases, 2007-02, Vol.44 (4), p.591-595

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

The Journal of infectious diseases, 2007-07, Vol.196 (2), p.304-312

2007

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients

Journal of antimicrobial chemotherapy, 2016-09, Vol.71 (9), p.2651-2653

2016

Link zum Volltext

Verfügbarkeit prüfen

Deficiency of C―C chemokine receptor 5 suppresses tumor development via inactivation of NF―κB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model

Carcinogenesis (New York), 2012-12, Vol.33 (12), p.2520-2528

2012

Link zum Volltext

Verfügbarkeit prüfen

The blocking of CXCR3 and CCR5 suppresses the infiltration of T lymphocytes in rat renal ischemia reperfusion

Nephrology, dialysis, transplantation, 2012-10, Vol.27 (10), p.3799-3806

2012

Link zum Volltext

Verfügbarkeit prüfen

HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

Journal of antimicrobial chemotherapy, 2014-08, Vol.69 (8), p.2191-2194

2014

Link zum Volltext

Verfügbarkeit prüfen

Response to Vicriviroc in Treatment-Experienced Subjects, as Determined by an Enhanced-Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211

The Journal of infectious diseases, 2009-12, Vol.200 (11), p.1724-1728

2009

Link zum Volltext

Verfügbarkeit prüfen

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

Journal of antimicrobial chemotherapy, 2010-04, Vol.65 (4), p.749-751

2010

Link zum Volltext

Verfügbarkeit prüfen

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

Journal of antimicrobial chemotherapy, 2012-01, Vol.67 (1), p.206-212

2012

Link zum Volltext

Verfügbarkeit prüfen

The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis

International immunology, 2005-08, Vol.17 (8), p.1023-1034

2005

Link zum Volltext

Verfügbarkeit prüfen

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

The Journal of infectious diseases, 2010-02, Vol.201 (4), p.590-599

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection

The Journal of infectious diseases, 2008-10, Vol.198 (8), p.1113-1122

2008

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection

American journal of health-system pharmacy, 2009-04, Vol.66 (8), p.715-726

2009

Link zum Volltext

Verfügbarkeit prüfen

Study on CCR5 analogs and affinity peptides

Protein engineering, design and selection, 2012-03, Vol.25 (3), p.97-105

2012

Link zum Volltext

Verfügbarkeit prüfen

Comment on: High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists

Journal of antimicrobial chemotherapy, 2010-09, Vol.65 (9), p.2056-2057

2010

Link zum Volltext

Verfügbarkeit prüfen

HIV-1 receptors and cell tropism

British medical bulletin, 2001-09, Vol.58 (1), p.43-59

2001

Link zum Volltext

Verfügbarkeit prüfen

Targeting the Chemokine Receptor CCR5: Good for HIV, What about Other Viruses?

The Journal of infectious diseases, 2011-01, Vol.203 (2), p.292-292

2011

Link zum Volltext

Verfügbarkeit prüfen

Response to “Case of Yellow Fever Vaccine-Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES Genes”

The Journal of infectious diseases, 2009-02, Vol.199 (4), p.601-601

2009

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc: integration of a new antiretroviral drug class into clinical practice

Journal of antimicrobial chemotherapy, 2008-06, Vol.61 (6), p.1187-1190

2008

Link zum Volltext

Verfügbarkeit prüfen

Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5

Journal of antimicrobial chemotherapy, 2010-03, Vol.65 (3), p.417-424

2010

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis Journals Complete

KollektionOxford Journals 2020 Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(37)
Science & Technology
(37)
Humans
(35)
Ccr5 Receptor Antagonists
(28)
Infectious Diseases
(28)
Microbiology
(28)
Hiv
(22)
Hiv Infections - Drug Therapy
(19)
Biological And Medical Sciences
(18)
Male
(17)
Medical Sciences
(16)
Female
(15)
Hiv-1 - Drug Effects
(15)
Immunology
(15)
Pharmacology & Pharmacy
(15)
Human Immunodeficiency Virus 1
(14)
Human Immunodeficiency Virus
(13)
Viral Diseases
(13)
Human Viral Diseases
(12)
Viral Diseases Of The Lymphoid Tissue And The Blood. Aids
(12)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Oxford Journals
(40)
MEDLINE
(40)
WK Lippincott Williams & Wilkins–Connect here FIRST to enable access
(40)
EZB Electronic Journals Library
(38)
Publisher's website
(17)
JSTOR
(15)
Ingenta
(12)
IngentaConnect Journals
(1)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)

Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application

Stabilization of atherosclerotic plaques: an update

Maraviroc versus Efavirenz, Both in Combination with Zidovudine-Lamivudine, for the Treatment of Antiretroviral-Naive Subjects with CCR5-tropic HIV-1 Infection

Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: 2008 Recommendations of an International AIDS Society-USA Panel

HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV-1-Infected, Treatment-Experienced Patients: AIDS Clinical Trials Group 5211

Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients

Deficiency of C―C chemokine receptor 5 suppresses tumor development via inactivation of NF―κB and inhibition of monocyte chemoattractant protein-1 in urethane-induced lung tumor model

The blocking of CXCR3 and CCR5 suppresses the infiltration of T lymphocytes in rat renal ischemia reperfusion

HIV-2 viral tropism influences CD4+ T cell count regardless of viral load

Response to Vicriviroc in Treatment-Experienced Subjects, as Determined by an Enhanced-Sensitivity Coreceptor Tropism Assay: Reanalysis of AIDS Clinical Trials Group A5211

Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists

CNS effects of a CCR5 inhibitor in HIV-infected subjects: a pharmacokinetic and cerebral metabolite study

The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis

Vicriviroc in Combination Therapy with an Optimized Regimen for Treatment-Experienced Subjects: 48-Week Results of the VICTOR-E1 Phase 2 Trial

Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment-Naive Subjects with HIV-1 Infection

Maraviroc: A coreceptor CCR5 antagonist for management of HIV infection

Study on CCR5 analogs and affinity peptides

Comment on: High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists

HIV-1 receptors and cell tropism

Targeting the Chemokine Receptor CCR5: Good for HIV, What about Other Viruses?

Response to “Case of Yellow Fever Vaccine-Associated Viscerotropic Disease with Prolonged Viremia, Robust Adaptive Immune Responses, and Polymorphisms in CCR5 and RANTES Genes”

Maraviroc: integration of a new antiretroviral drug class into clinical practice

Different selection patterns of resistance and cross-resistance to HIV-1 agents targeting CCR5

Aktive Filter

Suchergebnisse filtern